WEDNESDAY, SEPTEMBER 17TH

15:00
INTRODUCTION
J. TOUCHON, B. VELLAS, Z. KACHATURIAN

BIOMARKERS ON CLINICAL TRIALS IN ALZHEIMER’S DISEASE

ORAL COMMUNICATIONS

15:30
01 INTEREST OF CSF ABETA/TAU INDEX IN ALZHEIMER'S POSITIVE DIAGNOSIS
A. Gabelle (1,2,*) , S. Roche (1,3,*), C. Gény (2) , J. Touchon (2,4) , F. Portet (2) , S.Lehmann (1,3)
* The first two authors contributed equally to this work
(1) CNRS, Institut de Génétique Humaine UPR 1142, Montpellier, France(2) Service de Neurologie, CHU Gui de Chauliac, Montpellier, France (3) Laboratoire de Biochimie, CHU Saint Eloi, Montpellier, France (4) Faculté de Médecine, Montpellier, France

15:45
02 A MIXTURE MODELING APPROACH TO BIOMARKER ASSESSMENT REVEALS AN ALZHEIMER’S DISEASE SIGNATURE IN MORE THAN A THIRD OF COGNITIVELY NORMAL ELDERLY PEOPLE
G. de Meyer (1*) F. Shapiro (1), H. Vanderstichele (1), E. Vanmechelen (1), S. Engelborghs (2), PP de Deyn (2), L. Shaw (3), J. Trojanowski (3) and the Alzheimer’s Disease Neuroimaging Initiative (4)
(1) Innogenetics nv, Gent, Belgium; (2) Department of Neurology and Memory Clinic, (3) Middelheim General Hospital and Institute Born Bunge, (4) University of Antwerp, Belgium

16:00
03 RATE OF VENTRICULAR ENLARGEMENT: A COMPARISON BETWEEN MEASURES DERIVED FROM 3.0 TESLA AND 1.5 TESLA MRI IN SUBJECTS PARTICIPATING IN ADNI
S.M. Nestor (1), R. Rupsingh (1,2), M. Borrie (3,6), M.Smith (6), J. L. Wells (3,6), R. Bartha (1,2,4,5)
(1) Centre for Functional and Metabolic Mapping, Robarts Research Institute, London, Canada; (2) The Departments of Medical Biophysics, (3) Medicine, (4) Diagnostic Radiology and Nuclear Medicine, and (5) Psychiatry, University of Western Ontario, London, Canada; (6) Division of Aging, Rehabilitation, and Geriatric Care, Lawson Health Research Institute, London, Canada

16:15
04 EVOLUTION IN Aß40 LEVELS AND Aß42/Aß40 RATIO IN PLASMA IN RELATION TO THE DEVELOPMENT OF ALZHEIMER'S DISEASE: A MULTI-CENTER ASSESSMENT
K. Blennow (3*), G. de Meyer (1*), O. Hansson (2), L. Minthon (2), A. Wallin (3), H. Zetterberg (3), P. Lewezuk (4), H. Vandertischele (1), E. Vanmechelen (1), J. Kornhuber (4), J. Wiltfang (5)
(1) Innogenetics, Gent, Belgium, (2) Neuropsychiatric Clinic, Malmö University Hospital, Sweden, (3) Sahlgrenska University Hospital, Göteborg University, Sweden, (4) Department of Psychiatry, Universitätsklinikum Erlangen, (5) University of Erlangen-Nuremberg, Erlangen, Germany, (6) Kliniken/Institut der Universität Duisburg-Essen, Essen, Germany,
* These authors contributed equally to this study, underlined, presenting and corresponding author.

16:30 -17:00
Coffee break and Poster Session

LECTURES

17:00
L1 Use of biomarkers for Clinical Trials in Alzheimer’s disease
Kaj BLENNOW (Mölndal)

17:30
L2 Neuro imaging outcomes in Clinical Trials in Alzheimer’s disease
Giovanni FRISONI (Brescia)

18:00
L3 What can we learn from ADNI for Clinical Trials ?
Michael WEINER (San Fransisco)

COMPETITIVENESS CLUSTERS

18:30
Synergies between Industry, Biotech and Public Research communities for Innovative Projects. Status of projects in Alzheimer’s Disease.
J.Berthe*, J.Touchon** and projects partners
* Orpheme Biocluster, sanofi-aventis, Montpellier - ** U888 INSERM, CHU Montpellier

19:30
Welcome Reception